Golam Sharoar
Research Subjects
Golam Sharoar has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Il-Seon Park
Department of Biomedical Sciences, Chosun University, Gwangju, Republic of Korea
4 shared publications - Riqiang Yan
Department of Neuroscience, University of Connecticut, Farmington, Connecticut
4 shared publications Song Yub Shin
4 shared publicationsJohn Zhou
Department of Neuroscience, University of Connecticut Health, Farmington, CT., USA; Molecular Medicine Graduate Program, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH., USA
2 shared publicationsRiqiang Yan
Department of Neuroscience, University of Connecticut Health, Farmington, CT., USA
2 shared publicationsShahnawaz
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in npj Aging
Nipsnap 1 deficiency shifts neuronal and synaptic signaling toward inflammatory pathway and impairs cognitive functions in the aging brain
- 6 October 2026
- Published by Springer Nature in npj Aging
Open AccessNipsnap 1 deficiency shifts neuronal and synaptic signaling toward inflammatory pathway and impairs cognitive functions in the aging brain
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
A comparative study of medication profiles from AD, MCI, and non‐demented patients
Background: The ever‐increasing incidence of Alzheimer’s disease (AD) and the lack of effective therapeutics to treat the disease are leading to a “silver tsunami”. Current FDA‐approved drugs to treat the disease are limited as their benefit is simply momentary relief of the symptoms. Due to the chronic and progressive nature of AD, patients are routinely prescribed multiple non‐AD medications to preserve their ability to perform daily activities and to improve their quality of life. However, how those medications affect AD pathology remains unknown. In the present study, we have compared medication profiles of AD (n = 135), mild cognitive declined (MCI; n = 120), and non‐demented (n = 259) patients, with an aim to determine the effects of top‐ranked drugs on AD pathology.Methods: Study subjects (≥65 years) were recruited from an academic geriatric practice that is heavily focused on memory disorders. All subjects underwent for the following cognitive assessments: a) Clinical dementia rating scale (CDR), b) Mini‐Mental Status Examination (MMSE), c) logical memory test, d) digit span forward and backward, e) category fluency test, f) ordering test, g) trails A&B, and finally the Geriatric Depression Scale. Individual medication for each subject was listed and they were categorized into major drug classes. Statistical analysis was performed to determine the frequency of each drug in each class.Results: Eight top‐ranked drug classes were categorized from a list of 453 individual medications. Vitamins (30‐40%) and anti‐inflammatory (∼30%) drugs were the major categories for each cohort. Interestingly, 11% of drugs were proton pump inhibitors in non‐demented patients, and this decreased by 8% in MCI, and 5% in AD. We found a reduced (8%) Lipitor prescriptions for AD patients compared MCI (11%) and non‐demented (13%) patients. We are investigating the effects of these highly prescribed drugs on β‐amyloid production/aggregation, cytotoxicity, plaque load, and tau phosphorylation in vitro and in vivo using cell culture and AD mouse models.Conclusion: While the effects of routinely prescribed drugs on AD pathology are not well known, we found reduced vitamins, proton pump inhibitors, and Lipitor in the medication profiles of AD patients compared to the non‐AD population.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessA comparative study of medication profiles from AD, MCI, and non‐demented patients
Background: The ever‐increasing incidence of Alzheimer’s disease (AD) and the lack of effective therapeutics to treat the disease are leading to a “silver tsunami”. Current FDA‐approved drugs to treat the disease are limited as their benefit is simply momentary relief of the symptoms. Due to the chronic and progressive nature of AD, patients are routinely prescribed multiple non‐AD medications to preserve their ability to perform daily activities and to improve their quality of life. However, how those medications affect AD pathology remains unknown. In the present study, we have compared medication profiles of AD (n = 135), mild cognitive declined (MCI; n = 120), and non‐demented (n = 259) patients, with an aim to determine the effects of top‐ranked drugs on AD pathology.Methods: Study subjects (≥65 years) were recruited from an academic geriatric practice that is heavily focused on memory disorders. All subjects underwent for the following cognitive assessments: a) Clinical dementia rating scale (CDR), b) Mini‐Mental Status Examination (MMSE), c) logical memory test, d) digit span forward and backward, e) category fluency test, f) ordering test, g) trails A&B, and finally the Geriatric Depression Scale. Individual medication for each subject was listed and they were categorized into major drug classes. Statistical analysis was performed to determine the frequency of each drug in each class.Results: Eight top‐ranked drug classes were categorized from a list of 453 individual medications. Vitamins (30‐40%) and anti‐inflammatory (∼30%) drugs were the major categories for each cohort. Interestingly, 11% of drugs were proton pump inhibitors in non‐demented patients, and this decreased by 8% in MCI, and 5% in AD. We found a reduced (8%) Lipitor prescriptions for AD patients compared MCI (11%) and non‐demented (13%) patients. We are investigating the effects of these highly prescribed drugs on β‐amyloid production/aggregation, cytotoxicity, plaque load, and tau phosphorylation in vitro and in vivo using cell culture and AD mouse models.Conclusion: While the effects of routinely prescribed drugs on AD pathology are not well known, we found reduced vitamins, proton pump inhibitors, and Lipitor in the medication profiles of AD patients compared to the non‐AD population.
- 1 November 2021
- Published by Elsevier in Neurobiology of Aging
- Vol. 107, 21-29
Dynactin 6 deficiency enhances aging-associated dystrophic neurite formation in mouse brains
- 1 November 2021
- Published by Elsevier in Neurobiology of Aging
- Vol. 107, 21-29
Dynactin 6 deficiency enhances aging-associated dystrophic neurite formation in mouse brains
- 26 April 2021
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 37 (6) , 1703-1725
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Alzheimer’s disease (AD) is the most common dementia with currently no known cures or disease modifying treatments (DMTs), despite much time and effort from the field. Diagnosis and intervention of AD during the early pre-symptomatic phase of the disease is thought to be a more effective strategy. Therefore, the detection of biomarkers has emerged as a critical tool for monitoring the effect of new AD therapies, as well as identifying patients most likely to respond to treatment. The establishment of the amyloid/tau/neurodegeneration (A/T/N) framework in 2018 has codified the contexts of use of AD biomarkers in neuroimaging and bodily fluids for research and diagnostic purposes. Furthermore, a renewed drive for novel AD biomarkers and innovative methods of detection has emerged with the goals of adding additional insight to disease progression and discovery of new therapeutic targets. The use of biomarkers has accelerated the development of AD drugs and will bring new therapies to patients in need. This review highlights recent methods utilized to diagnose antemortem AD.
- 26 April 2021
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 37 (6) , 1703-1725
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Alzheimer’s disease (AD) is the most common dementia with currently no known cures or disease modifying treatments (DMTs), despite much time and effort from the field. Diagnosis and intervention of AD during the early pre-symptomatic phase of the disease is thought to be a more effective strategy. Therefore, the detection of biomarkers has emerged as a critical tool for monitoring the effect of new AD therapies, as well as identifying patients most likely to respond to treatment. The establishment of the amyloid/tau/neurodegeneration (A/T/N) framework in 2018 has codified the contexts of use of AD biomarkers in neuroimaging and bodily fluids for research and diagnostic purposes. Furthermore, a renewed drive for novel AD biomarkers and innovative methods of detection has emerged with the goals of adding additional insight to disease progression and discovery of new therapeutic targets. The use of biomarkers has accelerated the development of AD drugs and will bring new therapies to patients in need. This review highlights recent methods utilized to diagnose antemortem AD.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S2)
Dynactin 6 deficiency enhances tubular ER‐associated dystrophic neurites formation
Background: The formation of dystrophic neurites (DNs) is a contributing factor to synaptic dysfunction in Alzheimer’s disease (AD) patients’ brains. We have shown that tubular endoplasmic reticulum (ER) shaping proteins reticulon 3 (RTN3), REEP2 and REEP5 are participated in the formation DNs, named as RTN3 immunoreactive DNs or RIDNs. RIDNs are appeared as clustered or dispersed forms in AD and aging mouse brain, respectively. Ultrastructural investigation showed that RIDNs are constitute with abnormal clustering of tubular ER. The over expression of RTN3 accelerates aging associated disperse RIDNs formation in Tg‐RTN3 mouse brain hippocampus. To determine a molecule that may cause RTN3 mediated abnormal tubular ER clustering, we aimed to identify RTN3 interacting proteins and to elucidate its functional roles in tabular ER accumulation and RIDNs formation in aging and AD brain.Methods: Yeast two‐hybrid system, co‐immunoprecipitation, domain mapping and immune‐confocal studies to identify RTN3 interacting proteins. WB was performed to measure the protein level. Formation of RIDNs in mouse brains were detected using immuno‐confocal study. AAV9‐RTN3‐mCherry and AAV9‐DCTN‐GFP were injected at hippocampus of wild type mice to over expressed RTN3 and DCTN6.Results: We have identified that N‐terminal domain of RTN3 interacts with dynactin 6 (DCTN6), a protein component that involved in dynein‐mediated retrograde transport of cargo vesicles. Our immune‐confocal studies on DCTN6 and RTN3 over expressed cells and primary cultured neuron indicate that RTN3‐DCTN6 interaction likely mediates the tubular ER trafficking. The DCTN6 protein level decreases during aging and it reduces in hippocampus compared to cortical samples of the same age mice. To understand the functional roles of DCTN6 in RIDNs formation during aging and beta‐amyloid plaque deposition, DCTN6 deficient Tg‐RTN3 and 5xFAD mice were generated. Tg‐RTN3; DCTN6+/‐ showed reduced DCTN6 protein level and enhanced hippocampus specific RINDs formation compare to Tg‐RTN3; DCTN6+/+ mouse. We are investigating whether RIDNs formation are increases in DCTN6 deficient 5xFAD mice and whether AAV9‐DCTN6 overexpression reduces RIDNs formation in AAV9‐RTN3 overexpressed mouse brain.Conclusion: RTN3‐DCTN6 interaction likely mediates the tubular ER transport in axons and the DCTN6 deficiency is a contributing factor for tubular ER accumulation, RIDNs formation in AD and aging brain.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S2)
Dynactin 6 deficiency enhances tubular ER‐associated dystrophic neurites formation
Background: The formation of dystrophic neurites (DNs) is a contributing factor to synaptic dysfunction in Alzheimer’s disease (AD) patients’ brains. We have shown that tubular endoplasmic reticulum (ER) shaping proteins reticulon 3 (RTN3), REEP2 and REEP5 are participated in the formation DNs, named as RTN3 immunoreactive DNs or RIDNs. RIDNs are appeared as clustered or dispersed forms in AD and aging mouse brain, respectively. Ultrastructural investigation showed that RIDNs are constitute with abnormal clustering of tubular ER. The over expression of RTN3 accelerates aging associated disperse RIDNs formation in Tg‐RTN3 mouse brain hippocampus. To determine a molecule that may cause RTN3 mediated abnormal tubular ER clustering, we aimed to identify RTN3 interacting proteins and to elucidate its functional roles in tabular ER accumulation and RIDNs formation in aging and AD brain.Methods: Yeast two‐hybrid system, co‐immunoprecipitation, domain mapping and immune‐confocal studies to identify RTN3 interacting proteins. WB was performed to measure the protein level. Formation of RIDNs in mouse brains were detected using immuno‐confocal study. AAV9‐RTN3‐mCherry and AAV9‐DCTN‐GFP were injected at hippocampus of wild type mice to over expressed RTN3 and DCTN6.Results: We have identified that N‐terminal domain of RTN3 interacts with dynactin 6 (DCTN6), a protein component that involved in dynein‐mediated retrograde transport of cargo vesicles. Our immune‐confocal studies on DCTN6 and RTN3 over expressed cells and primary cultured neuron indicate that RTN3‐DCTN6 interaction likely mediates the tubular ER trafficking. The DCTN6 protein level decreases during aging and it reduces in hippocampus compared to cortical samples of the same age mice. To understand the functional roles of DCTN6 in RIDNs formation during aging and beta‐amyloid plaque deposition, DCTN6 deficient Tg‐RTN3 and 5xFAD mice were generated. Tg‐RTN3; DCTN6+/‐ showed reduced DCTN6 protein level and enhanced hippocampus specific RINDs formation compare to Tg‐RTN3; DCTN6+/+ mouse. We are investigating whether RIDNs formation are increases in DCTN6 deficient 5xFAD mice and whether AAV9‐DCTN6 overexpression reduces RIDNs formation in AAV9‐RTN3 overexpressed mouse brain.Conclusion: RTN3‐DCTN6 interaction likely mediates the tubular ER transport in axons and the DCTN6 deficiency is a contributing factor for tubular ER accumulation, RIDNs formation in AD and aging brain.
- 21 March 2019
- Published by Springer Nature in Molecular Psychiatry
- Vol. 24 (9) , 1369-1382
Sequential formation of different layers of dystrophic neurites in Alzheimer’s brains
Alzheimer’s disease (AD) is characterized by the presence of neuritic plaques in which dystrophic neurites (DNs) are typical constituents. We recently showed that DNs labeled by antibodies to the tubular endoplasmic reticulum (ER) protein reticulon-3 (RTN3) are enriched with clustered tubular ER. However, multi-vesicle bodies are also found in DNs, suggesting that different populations of DNs exist in brains of AD patients. To understand how different DNs evolve to surround core amyloid plaques, we monitored the growth of DNs in AD mouse brains (5xFAD and APP/PS1ΔE9 mice) by multiple approaches, including two-dimensional and three-dimensional (3D) electron microscopy (EM). We discovered that a pre-autophagosome protein ATG9A was enriched in DNs when a plaque was just beginning to develop. ATG9A-positive DNs were often closer to the core amyloid plaque, whereas RTN3 immunoreactive DNs were mostly located in the outer layers of ATG9A-positive DNs. Proteins such as RAB7 and LC3 appeared in DNs at later stages during plaque growth, likely accumulated as a part of large autophagy vesicles, and were distributed relatively furthest from the core amyloid plaque. Reconstructing the 3D structure of different morphologies of DNs revealed that DNs in AD mouse brains were constituted in three layers that are distinct by enriching different types of vesicles, as validated by immune-EM methods. Collectively, our results provide the first evidence that DNs evolve from dysfunctions of pre-autophagosomes, tubular ER, mature autophagosomes, and the ubiquitin proteasome system during plaque growth.
- 21 March 2019
- Published by Springer Nature in Molecular Psychiatry
- Vol. 24 (9) , 1369-1382
Sequential formation of different layers of dystrophic neurites in Alzheimer’s brains
Alzheimer’s disease (AD) is characterized by the presence of neuritic plaques in which dystrophic neurites (DNs) are typical constituents. We recently showed that DNs labeled by antibodies to the tubular endoplasmic reticulum (ER) protein reticulon-3 (RTN3) are enriched with clustered tubular ER. However, multi-vesicle bodies are also found in DNs, suggesting that different populations of DNs exist in brains of AD patients. To understand how different DNs evolve to surround core amyloid plaques, we monitored the growth of DNs in AD mouse brains (5xFAD and APP/PS1ΔE9 mice) by multiple approaches, including two-dimensional and three-dimensional (3D) electron microscopy (EM). We discovered that a pre-autophagosome protein ATG9A was enriched in DNs when a plaque was just beginning to develop. ATG9A-positive DNs were often closer to the core amyloid plaque, whereas RTN3 immunoreactive DNs were mostly located in the outer layers of ATG9A-positive DNs. Proteins such as RAB7 and LC3 appeared in DNs at later stages during plaque growth, likely accumulated as a part of large autophagy vesicles, and were distributed relatively furthest from the core amyloid plaque. Reconstructing the 3D structure of different morphologies of DNs revealed that DNs in AD mouse brains were constituted in three layers that are distinct by enriching different types of vesicles, as validated by immune-EM methods. Collectively, our results provide the first evidence that DNs evolve from dysfunctions of pre-autophagosomes, tubular ER, mature autophagosomes, and the ubiquitin proteasome system during plaque growth.
- 24 November 2016
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
- Vol. 28 (2) , 145-154
Effects of altered RTN3 expression on BACE1 activity and Alzheimer’s neuritic plaques
Reticulon 3 (RTN3), which is a member of the reticulon family of proteins, has a biochemical function of shaping tubular endoplasmic reticulum. RTN3 has also been found to interact with β-site amyloid precursor protein cleaving enzyme 1 (BACE1), which initiates the generation of β-amyloid peptides (Aβ) from amyloid precursor protein. Aβ is the major proteinaceous component in neuritic plaques, which constitute one of the major pathological features in brains of Alzheimer’s disease (AD) patients. Mice deficient in or overexpressing RTN3 have altered amyloid deposition through effects on BACE1 expression and activity. In this review, we will summarize the current findings concerning the role of RTN3 in AD pathogenesis and demonstrate that RTN3 protein levels act as age-dependent modulators of BACE1 activity and Aβ deposition during the pathogenic progression of AD.
- 24 November 2016
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
- Vol. 28 (2) , 145-154
Effects of altered RTN3 expression on BACE1 activity and Alzheimer’s neuritic plaques
Reticulon 3 (RTN3), which is a member of the reticulon family of proteins, has a biochemical function of shaping tubular endoplasmic reticulum. RTN3 has also been found to interact with β-site amyloid precursor protein cleaving enzyme 1 (BACE1), which initiates the generation of β-amyloid peptides (Aβ) from amyloid precursor protein. Aβ is the major proteinaceous component in neuritic plaques, which constitute one of the major pathological features in brains of Alzheimer’s disease (AD) patients. Mice deficient in or overexpressing RTN3 have altered amyloid deposition through effects on BACE1 expression and activity. In this review, we will summarize the current findings concerning the role of RTN3 in AD pathogenesis and demonstrate that RTN3 protein levels act as age-dependent modulators of BACE1 activity and Aβ deposition during the pathogenic progression of AD.
- Open Access
- 1 December 2015
- Published by Springer Nature in Molecular Psychiatry
- Vol. 21 (9) , 1263-1271
Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimer’s disease
Pathological features in Alzheimer’s brains include mitochondrial dysfunction and dystrophic neurites (DNs) in areas surrounding amyloid plaques. Using a mouse model that overexpresses reticulon 3 (RTN3) and spontaneously develops age-dependent hippocampal DNs, here we report that DNs contain both RTN3 and REEPs, topologically similar proteins that can shape tubular endoplasmic reticulum (ER). Importantly, ultrastructural examinations of such DNs revealed gradual accumulation of tubular ER in axonal termini, and such abnormal tubular ER inclusion is found in areas surrounding amyloid plaques in biopsy samples from Alzheimer’s disease (AD) brains. Functionally, abnormally clustered tubular ER induces enhanced mitochondrial fission in the early stages of DN formation and eventual mitochondrial degeneration at later stages. Furthermore, such DNs are abrogated when RTN3 is ablated in aging and AD mouse models. Hence, abnormally clustered tubular ER can be pathogenic in brain regions: disrupting mitochondrial integrity, inducing DNs formation and impairing cognitive function in AD and aging brains.
- 1 December 2015
- Published by Springer Nature in Molecular Psychiatry
- Vol. 21 (9) , 1263-1271
Open AccessDysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimer’s disease
Pathological features in Alzheimer’s brains include mitochondrial dysfunction and dystrophic neurites (DNs) in areas surrounding amyloid plaques. Using a mouse model that overexpresses reticulon 3 (RTN3) and spontaneously develops age-dependent hippocampal DNs, here we report that DNs contain both RTN3 and REEPs, topologically similar proteins that can shape tubular endoplasmic reticulum (ER). Importantly, ultrastructural examinations of such DNs revealed gradual accumulation of tubular ER in axonal termini, and such abnormal tubular ER inclusion is found in areas surrounding amyloid plaques in biopsy samples from Alzheimer’s disease (AD) brains. Functionally, abnormally clustered tubular ER induces enhanced mitochondrial fission in the early stages of DN formation and eventual mitochondrial degeneration at later stages. Furthermore, such DNs are abrogated when RTN3 is ablated in aging and AD mouse models. Hence, abnormally clustered tubular ER can be pathogenic in brain regions: disrupting mitochondrial integrity, inducing DNs formation and impairing cognitive function in AD and aging brains.
- Open Access
- 15 October 2014
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 34 (42) , 13954-13962
Impact of RTN3 Deficiency on Expression of BACE1 and Amyloid Deposition
Reticulon 3 (RTN3) has previously been shown to interact with BACE1 and negatively regulate BACE1 activity. To what extent RTN3 deficiency affects BACE1 activity is an intriguing question. In this study, we aimed to address this by generating RTN3-null mice. Mice with complete deficiency of RTN3 grow normally and have no obviously discernible phenotypes. Morphological analyses of RTN3-null mice showed no significant alterations in cellular structure, although RTN3 is recognized as a protein contributing to the shaping of tubular endoplasmic reticulum. Biochemical analysis revealed that RTN3 deficiency increased protein levels of BACE1. This elevation of BACE1 levels correlated with enhanced processing of amyloid precursor protein at the β-secretase site. We also demonstrated that RTN3 deficiency in Alzheimer's mouse models facilitates amyloid deposition, further supporting anin vivorole of RTN3 in the regulation of BACE1 activity. Since it has been shown that RTN3 monomer is reduced in brains of Alzheimer's patients, our results suggest that long-lasting reduction of RTN3 levels has adverse effects on BACE1 activity and may contribute to Alzheimer's pathogenesis.
- 15 October 2014
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 34 (42) , 13954-13962
Open AccessImpact of RTN3 Deficiency on Expression of BACE1 and Amyloid Deposition
Reticulon 3 (RTN3) has previously been shown to interact with BACE1 and negatively regulate BACE1 activity. To what extent RTN3 deficiency affects BACE1 activity is an intriguing question. In this study, we aimed to address this by generating RTN3-null mice. Mice with complete deficiency of RTN3 grow normally and have no obviously discernible phenotypes. Morphological analyses of RTN3-null mice showed no significant alterations in cellular structure, although RTN3 is recognized as a protein contributing to the shaping of tubular endoplasmic reticulum. Biochemical analysis revealed that RTN3 deficiency increased protein levels of BACE1. This elevation of BACE1 levels correlated with enhanced processing of amyloid precursor protein at the β-secretase site. We also demonstrated that RTN3 deficiency in Alzheimer's mouse models facilitates amyloid deposition, further supporting anin vivorole of RTN3 in the regulation of BACE1 activity. Since it has been shown that RTN3 monomer is reduced in brains of Alzheimer's patients, our results suggest that long-lasting reduction of RTN3 levels has adverse effects on BACE1 activity and may contribute to Alzheimer's pathogenesis.
- 1 October 2013
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 538 (1) , 41-48
The inhibitory effects of Escherichia coli maltose binding protein on β-amyloid aggregation and cytotoxicity
- 1 October 2013
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 538 (1) , 41-48
The inhibitory effects of Escherichia coli maltose binding protein on β-amyloid aggregation and cytotoxicity